File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population

TitleRotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population
Authors
Keywords3Years
Efficacy
Gastroenteritis
Rix4414
Rotavirus
Issue Date2012
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2012, v. 30 n. 30, p. 4552-4557 How to Cite?
Abstract
RIX4414 (Rotarix™), has shown high efficacy during the first 2-years of life. A 2-year randomized, double-blind, placebo-controlled trial in Singapore, Hong Kong, and Taiwan was extended for another year. Infants (6-17. weeks) received 2-doses (1-2. months apart) of RIX4414 (n= 5359) or placebo (n= 5349). During the third-year follow-up, 4359 (RIX4414) and 4328 (placebo) infants were monitored. 64 (1.2%) and 2 (0.04%) infants in the placebo and RIX4414 groups, respectively, reported severe rotavirus-gastroenteritis (RVGE), resulting in a vaccine efficacy of 96.9% (95% CI [88.3-99.6]). Efficacy was 100% (67.5-100) in the third-year. RIX4414 was efficacious against G1 (100.0% [84.8-100]) and pooled non-G1 RV types (94.9% [80.2-99.4]). This study shows that the vaccine is highly efficacious, regardless of circulating RV-types, up to the first 3. years of life in affluent Asian urban populations. © 2012 Elsevier Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/170465
ISSN
2013 Impact Factor: 3.485
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPhua, KBen_US
dc.contributor.authorLim, FSen_US
dc.contributor.authorLau, YLen_US
dc.contributor.authorNelson, EASen_US
dc.contributor.authorHuang, LMen_US
dc.contributor.authorQuak, SHen_US
dc.contributor.authorLee, BWen_US
dc.contributor.authorDoorn, LJVen_US
dc.contributor.authorTeoh, YLen_US
dc.contributor.authorTang, Hen_US
dc.contributor.authorSuryakiran, PVen_US
dc.contributor.authorSmolenov, IVen_US
dc.contributor.authorBock, HLen_US
dc.contributor.authorHan, HHen_US
dc.date.accessioned2012-10-30T06:09:11Z-
dc.date.available2012-10-30T06:09:11Z-
dc.date.issued2012en_US
dc.identifier.citationVaccine, 2012, v. 30 n. 30, p. 4552-4557en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/170465-
dc.description.abstractRIX4414 (Rotarix™), has shown high efficacy during the first 2-years of life. A 2-year randomized, double-blind, placebo-controlled trial in Singapore, Hong Kong, and Taiwan was extended for another year. Infants (6-17. weeks) received 2-doses (1-2. months apart) of RIX4414 (n= 5359) or placebo (n= 5349). During the third-year follow-up, 4359 (RIX4414) and 4328 (placebo) infants were monitored. 64 (1.2%) and 2 (0.04%) infants in the placebo and RIX4414 groups, respectively, reported severe rotavirus-gastroenteritis (RVGE), resulting in a vaccine efficacy of 96.9% (95% CI [88.3-99.6]). Efficacy was 100% (67.5-100) in the third-year. RIX4414 was efficacious against G1 (100.0% [84.8-100]) and pooled non-G1 RV types (94.9% [80.2-99.4]). This study shows that the vaccine is highly efficacious, regardless of circulating RV-types, up to the first 3. years of life in affluent Asian urban populations. © 2012 Elsevier Ltd.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.subject3Yearsen_US
dc.subjectEfficacyen_US
dc.subjectGastroenteritisen_US
dc.subjectRix4414en_US
dc.subjectRotavirusen_US
dc.titleRotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian populationen_US
dc.typeArticleen_US
dc.identifier.emailLau, YL:lauylung@hkucc.hku.hken_US
dc.identifier.authorityLau, YL=rp00361en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.vaccine.2012.03.030en_US
dc.identifier.pmid22497874-
dc.identifier.scopuseid_2-s2.0-84862020627en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84862020627&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume30en_US
dc.identifier.issue30en_US
dc.identifier.spage4552en_US
dc.identifier.epage4557en_US
dc.identifier.isiWOS:000310117100020-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridPhua, KB=7003538202en_US
dc.identifier.scopusauthoridLim, FS=7006112665en_US
dc.identifier.scopusauthoridLau, YL=7201403380en_US
dc.identifier.scopusauthoridNelson, EAS=7402264387en_US
dc.identifier.scopusauthoridHuang, LM=24281436100en_US
dc.identifier.scopusauthoridQuak, SH=35512093800en_US
dc.identifier.scopusauthoridLee, BW=7405437980en_US
dc.identifier.scopusauthoridDoorn, LJV=16244783500en_US
dc.identifier.scopusauthoridTeoh, YL=6603277028en_US
dc.identifier.scopusauthoridTang, H=15828580700en_US
dc.identifier.scopusauthoridSuryakiran, PV=26022588400en_US
dc.identifier.scopusauthoridSmolenov, IV=23499725700en_US
dc.identifier.scopusauthoridBock, HL=7201825902en_US
dc.identifier.scopusauthoridHan, HH=8545352800en_US
dc.identifier.citeulike10784864-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats